Imagion Funding Update
March 7, 2023
Highlights: Shareholder entitlement offer seeking to raise up to $2.4 million Funding facility of up to $15 million secured with Mercer Street Global Opportunity Fund,
Category: News
Imagion Secures Growth Funding
March 7, 2023
Highlights: Imagion secures a funding facility of up to $15 million to support next phase of clinical and oncology pipeline development Funding Facility includes: $1.5 million
Imagion Receives 2nd CSIRO Federal Government Grant for Prostate Cancer Project
March 1, 2023
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that it
Imagion Biosystems 2022 Annual Report
February 28, 2023
Imagion Biosystems has released its Annual Report for the year ending 31 December 2022. [See linked documents below] 2022 Research & Development Highlights: March 2022
Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems
February 10, 2023
Tim Boreham has taken another look at Imagion Biosystems in his latest “Dr. Boreham’s Crucible” column on Biotech Daily. In the column, Tim discusses the
Biotech Daily — Imagion Trial Review Backs Magsense for All Cancer MRI
February 6, 2023
“Imagion says it will prioritize development of its Magsense nanoparticle technology as imaging agents for mainstream clinical magnetic resonance imaging (MRI) scanners. Imagion said that
Positive independent review sets priority path to market for MagSense® Technology
February 5, 2023
https://www.youtube.com/watch?v=g8SnQWwJh68 Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic
Quarterly Activity Report – Quarter Ending 31 December 2022
January 30, 2023
Highlights: Imagion presented results from MagSense® HER2 Phase I study at global breast cancer meeting showing safety and detectability Tasks expert panel of radiologists with
Imagion presents MagSense® interim study results at breast cancer meeting
December 8, 2022
Imaging agent aids in resolving nodal status MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of
Quarterly Activity Report – Quarter Ending 30 September 2022
October 28, 2022
Highlights: Imagion presented prostate cancer research data at World Molecular Imaging Conference (WMIC) Receipt of $2.5 million R&D tax incentive (post-quarter end) MELBOURNE – Imagion